The Family Journal
July 1, 2019
Katie Almond, Robert Allan
7 citations
This article explores incorporating 3,4-methylenedioxymethamphetamine (MDMA) as an adjunct in emotionally focused couples therapy (EFT) with clients in which at least one participant has endured a traumatic experience and reports symptoms of post-traumatic stress disorder (PTSD). Despite classification as a Schedule I drug on the Controlled Substances Act (CSA), in 2017 the U.S. Food and Drug...
Neuropharmacology
June 2019
Daniel W Curry, Laís F. Berro, Andie R Belkoff et al.
The recreational drug 3,4-methylenedioxymethamphetamine (MDMA) has well documented prosocial effects and is currently under clinical investigation as a treatment for patients with PTSD, autism, and other conditions. Early clinical trials have found that MDMA-assisted therapy may have robust long-lasting therapeutic effects, yet the mechanism by which acute treatments produce these long-term...
Behavioural Pharmacology
June 1, 2019
Susan Schenk, Quenten Highgate
2 citations
Most studies on discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) have been conducted using a relatively low dose (1.5 mg/kg), and those studies have invariably implicated serotonergic mechanisms. In contrast, dopaminergic mechanisms mediate the discriminative stimulus effects of amphetamine (AMPH). Some studies have suggested that the discriminative stimulus effects...
Journal of Psychopharmacology
April 30, 2019
Dino Luethi, Karolina E. Kolaczynska, Melanie Walter et al.
39 citations
Background: Amphetamine analogs with a 3,4-methylenedioxy ring-substitution are among the most popular illicit drugs of abuse, exerting stimulant and entactogenic effects. Enzymatic N-demethylation or opening of the 3,4-methylenedioxy ring via O-demethylenation gives rise to metabolites that may be pharmacologically active. Indeed, previous studies in rats show that specific metabolites of...
Drug Testing and Analysis
April 22, 2019
Lewis Couchman, Anca Frinculescu, Catarina Sobreira et al.
35 citations
Abstract 3,4‐Methylenedioxymethamphetamine (MDMA, Ecstasy) tablets are widely used recreationally, and not only vary in appearance, but also in MDMA content. Recently, the prevalence of high‐content tablets is of concern to public health authorities. To compare UK data with other countries, we evaluated MDMA content of 412 tablets collected from the UK, 2001–2018, and investigated within‐batch...
PLoS One
April 13, 2019
Patrick Vizeli, Matthias E. Liechti
37 citations
Methylenedioxymethamphetamine (MDMA) increases oxytocin, empathy, and prosociality. Oxytocin plays a critical role in emotion processing and social behavior and has been shown to mediate the prosocial effects of MDMA in animals. Genetic variants, such as single-nucleotide polymorphisms (SNPs), of the oxytocin receptor (OXTR) may influence the emotional and social effects of MDMA in humans. The...
Neuroimage
April 4, 2019
Ottavia Dipasquale, Pierluigi Selvaggi, Mattia Veronese et al.
79 citations
One of the main limitations of pharmacological fMRI is its inability to provide a molecular insight into the main effect of compounds, leaving an open question about the relationship between drug effects and haemodynamic response. The aim of this study is to investigate the acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on functional connectivity (FC) using a novel multimodal method...
Nature
April 3, 2019
Romain Nardou, Eastman M. Lewis, Rebecca Rothhaas et al.
343 citations
A critical period is a developmental epoch during which the nervous system is expressly sensitive to specific environmental stimuli that are required for proper circuit organization and learning. Mechanistic characterization of critical periods has revealed an important role for exuberant brain plasticity during early development, and for constraints that are imposed on these mechanisms as the...
The FASEB Journal
April 1, 2019
Madeline M. Pantoni, Stephan G Anagnostaras
±3,4‐methylenedioxymethamphetamine (MDMA) is a recreational drug that is also being pursued as a therapeutic for PTSD and other mood and anxiety disorders. Despite strong evidence of its therapeutic potential, these pursuits are hindered by evidence that MDMA produces robust neurotoxicity and cognitive deficits at high doses. These findings, however, may not generalize to typical recreational...
Frontiers in Psychiatry
March 20, 2019
Ben Sessa, David Nutt, Laurie Higbed
141 citations
This paper provides a brief review of the history, proposed pharmacological mechanisms, safety issues, and clinical applications of the medicine 3,4-methylenedioxymethamphetamine (MDMA). Most clinical MDMA research in patients to date has focused on MDMA-assisted psychotherapy to treat posttraumatic stress disorder (PTSD). In this review paper other potential therapeutic applications for MDMA...